Experimental cancer drug begins first human testing
Disease control
Not yet recruiting
This is the first study in humans to test a new cancer drug called T320. The trial aims to find the safest dose and check for side effects in 150 patients with advanced solid tumors who have no effective standard treatments left. Patients will receive T320 injections every two we…
Phase: PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC